Adage Capital Partners
OKUR

Adage Capital Partners’s OnKure Therapeutics OKUR Stock Holding History

Adage Capital Partners’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.49M Hold
1,204,819
– – 0.01% 799
2026
Q1 		$4.99M Buy
+1,204,819
New +$3.72M 0.01% 774
2023
Q4 		– Sell
-6,500
Closed -$495K – 941
2023
Q3 		$495K Buy
+6,500
New +$442K ﹤0.01% 782

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners's OKUR Position: Q2 2026 in Review

Adage Capital Partners held its OnKure Therapeutics (OKUR) position steady in Q2 2026 at 1,204,819 shares worth $5.49M. The position accounts for 0.01% of the portfolio, ranked #799.

Adage Capital Partners first reported a position in OKUR in Q3 2023 and has held it in 3 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Adage Capital Partners held 1,204,819 shares of OnKure Therapeutics worth $5.49M as of Q2 2026.
  • Adage Capital Partners left its OnKure Therapeutics share count unchanged in Q2 2026.
  • OnKure Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #799 holding.
  • Adage Capital Partners first reported a position in OnKure Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.